At TIDES Asia 2025 conference, our founder and CEO Dr. Weimin Wang delivered a presentation on the topic of “LEAD (Ligand- and Enhancer-Assisted Delivery) enables efficient siRNA delivery to immune cells by targeting a cell type-specific receptors”.
In this presentation, he introduced SanegeneBio’s LEAD platform. Extrahepatic delivery of siRNA presents significant challenges, particularly in targeting immune cells. Sanegene’s innovative LEAD™ (Ligand and Enhancer Assisted Delivery) technology facilitates precise siRNA delivery to specific immune cells, including macrophages and dendritic cells, by targeting cell-specific receptors. Our studies demonstrate that, under physiological conditions, the LEAD platform efficiently delivers siRNA molecules specifically to tissue resident macrophages in both rodent and non-human primates, robustly silencing the target genes. Furthermore, under pathological conditions, our platform shows specific and efficient delivery of siRNA to residential and infiltrating monocyte-derived macrophages in an obese mouse model, and tumor-associated macrophages in allograft tumor models. This advanced delivery technology significantly enhances the therapeutic potential of siRNA, paving the way for new therapeutic strategies. #https://lnkd.in/gs29ds5R
